消息面上，商务部等九部门发布关于促进药品零售行业高质量发展的意见提出，优化药品营销体系。倡 导医药生产企业与全国或区域大型医药流通企业深度合作，以市场为导向规范药品购、销价格体系，促 进药品零售行业跨省、跨地区公平竞争，引导零售药品价格保持合理水平。鼓励创新药、参比制剂等药 品进零售药店销售渠道。鼓励医药电商平台开放数据接口，加强线上、线下药品零售价与省级医药采购 平台挂网价的联动监测，加强定点药店医保药品量价比较指数和药品比价小程序的推广应用。 江海证券表示，我们认为随着全球生物医药投融资环境逐步回暖，中国创新药企业出海已成为核心发展 趋势。新年首周，国内创新药领域便落地5项对外授权合作，涵盖小分子抑制剂、单抗、双抗、ADC和 RDC等多个技术领域，充分展现了中国在生物医药各技术领域的全球领先布局实力。 （文章来源：21世纪经济报道） 1月23日，A股三大指数集体上涨，中证创新药产业指数截至发稿上涨1.37%，该指数成分股中，昭衍新 药上涨超5%，贝达药业、君实生物-U、荣昌生物、泰格医药、沃森生物等跟涨。 相关ETF方面，创新药ETF（159992）截至发稿涨1.17%，成交额超1.5亿元，盘中交投活跃。 ...

资金流向方面，Wind数据显示，该ETF近5个交易日连续获资金净流入，累计"吸金"近9亿元。 创新药ETF（159992）紧密跟踪中证创新药产业指数。该指数选取主营业务涉及创新药研发的上市公司 作为待选样本，按照市值排序选取不超过50家最具代表性公司作为样本股，以反映创新药产业上市公司 的整体表现，为投资者提供新的投资标的。 1月13日，A股创新药板块盘初持续走强。 热门ETF中，创新药ETF（159992）持续拉升，截至发稿涨超2%，成交额超2亿元，交投活跃。 成分股中，荣昌生物涨超16%，泰格医药涨超6%，药明康德涨超5%，安科生物、康龙化成、昭衍新 药、三生国健等股涨幅居前。 此外，1月12日，药明康德(603259.SH)发布2025年度业绩预告，预计归属于上市公司股东的净利润为 191.51亿元，同比增长约102.65%。 国信证券表示，关注JPM年会及创新药在海外的临床进展。中国创新药产业已经体现出长期向好的发展 趋势，并在近年集中体现在BD交易的爆发式增长。值得注意的是，对于大部分国产创新药，对外授权 通常只是全球开发的起点，合作伙伴在海外的开发进度，以及后续全球临床数据的读出可以进一步加强 产 ...

12月9日早盘，A股、港股创新药概念均表现活跃。热门ETF中，创新药ETF（159992）截至9:57涨约 1%，成交额超1.5亿元。 成分股来看，迪哲医药、恒瑞医药、泰格医药等涨幅居前；通化金马、人福医药、特宝生物等小幅领 跌。 消息面上，2025年国家医保药品目录及首版商保创新药目录在广州发布。2025年国家医保药品目录成功 新增114种药品，有50种是一类创新药，总体成功率88%，较2024年的76%明显提高。19种药品纳入首 版商保创新药目录。 每日经济新闻 中信建投认为，国家医保谈判成功率创新高，商保目录有望成为重要增量，政策鼓励创新药发展。与此 同时，中国创新药管线国际化竞争力持续提升，出海模式持续升级，新技术推动行业快速发展。看好相 关创新药及制药企业。 资料显示，创新药ETF（159992，场外联接A类：012781；C类：012782）紧密跟踪中证创新药产业指 数，选取不超过50只最具代表性上市公司证券作为指数样本，以反映创新药产业上市公司证券的整体表 现。 ...

Core Viewpoint - The 76th AASLD conference showcased significant advancements in China's innovative drug sector, particularly in hepatitis B treatment, indicating a positive outlook for the industry moving forward [1][4][5]. Group 1: Performance of Chinese Innovative Drug Companies - Chinese research teams made notable contributions at the AASLD 2025 conference, presenting findings on hepatitis B and other liver diseases, with several experts receiving prestigious awards [4]. - Breakthrough drugs and clinical data were highlighted, including HepaPrax combined with interferon achieving "sterilizing cure" for hepatitis B, and AHB-137 showing a 39% sustained clearance rate post-treatment [4][5]. Group 2: Future Outlook for the Innovative Drug Sector - The innovative drug sector is benefiting from several positive industry trends, including a sustained "going global" momentum, with overseas licensing deals reaching $104.2 billion and upfront payments totaling $8.1 billion by October 2025 [8]. - The pharmaceutical sector reported a net profit of 40.51 billion yuan in Q3 2025, a 7.67% year-on-year increase, with expectations for continued growth in innovative drug commercialization and overseas deals [8]. - Ongoing policy support is anticipated, with upcoming insurance negotiations expected to enhance the accessibility and affordability of high-priced innovative drugs [8]. - The innovative drug sector has experienced a three-month adjustment period, which is viewed as healthy, with expectations for a new round of growth as market dynamics shift [8].

Core Viewpoint - The innovative pharmaceutical sector has become a key driver of revenue growth for listed companies, with some companies reporting that innovative drug revenue has surpassed 50% of total revenue, indicating a significant shift towards innovation-driven business models [1][3]. Group 1: Performance Highlights - In the first half of 2025, multiple innovative pharmaceutical companies in the A-share market reported both revenue and profit growth, with the proportion of innovative drugs continuing to rise [3]. - A representative product, the BTK inhibitor Zebutini, achieved global sales of 12.527 billion yuan in the first half of 2025, marking a year-on-year increase of 56.2% [3]. - In the Hong Kong stock market, 39 innovative pharmaceutical companies reported total revenue of 152.061 billion yuan in the first half of 2025, a year-on-year growth of 7.66%, with net profit attributable to shareholders reaching 28.266 billion yuan, a significant increase of 54.37% [3]. Group 2: Market Signals - The strong performance of innovative pharmaceutical companies indicates that the long-term innovation-driven strategies are beginning to yield results, with sustained R&D investments gaining market recognition [3][6]. - Increased health awareness among residents and supportive healthcare policies are contributing to the growing market demand for innovative drugs [3]. Group 3: Growth Drivers - R&D capabilities are improving in both quantity and quality, with China becoming a global center for new drug development, particularly in areas like ADC and multi-antibody technologies [7]. - Continuous policy support from the government, including 32 specific measures aimed at enhancing the innovative pharmaceutical sector, is fostering overall industry vitality [7]. - The trend of Chinese innovative drugs entering international markets is expected to enhance company performance through upfront and milestone payments from overseas collaborations [7]. Group 4: Market Potential - The Chinese innovative pharmaceutical market is projected to exceed 750 billion yuan in 2025, representing an 18% increase from 2024, and is expected to capture 6% of the global market share [8]. - By 2030, the market size is anticipated to surpass 2.3 trillion yuan, with a compound annual growth rate of 15% from 2025 to 2030 [8]. - The transition from "Made in China" to "Created in China" signifies the beginning of a new growth phase for the industry, with several quarters of growth expected to be relatively certain [8].

Core Viewpoint - The Hong Kong Innovation Drug Index has shown a remarkable increase of 101.93% year-to-date, indicating a strong performance in the innovative pharmaceutical sector, which is expected to continue growing due to favorable factors [1]. Group 1: Industry Trends - The innovative drug sector is identified as a clear trend with significant future growth potential within the pharmaceutical industry [1]. - The number of approved innovative drugs has significantly increased, with 43 approvals in the first half of the year, representing a 59% year-on-year growth, nearing the total of 48 expected for the entire year of 2024 [2]. - The approval process for innovative drugs has been expedited, reducing the application review time from 200 working days to 60 in 11 pilot provinces, enhancing market access for new drugs [2]. Group 2: Financial Performance - Pharmaceutical companies have successfully reduced sales and financial costs, contributing to improved profit margins, while R&D expenses have increased, reflecting ongoing investment in innovation [1]. - The total transaction amount for overseas licensing by Chinese pharmaceutical companies reached $51.9 billion in 2024, a 36% increase from the previous year, with the first half of 2025 already surpassing last year's total at $60.8 billion [2]. Group 3: Investment Opportunities - The pharmaceutical and biotechnology industry is expected to stabilize and grow in 2025, supported by favorable policies for innovative drug development and medical equipment updates [3]. - Investment vehicles such as the Hong Kong Innovation Drug ETF and its associated funds are positioned to capture growth in the innovative drug market while diversifying individual stock risks [3]. - The Hong Kong Innovation Drug ETF will undergo a share split on August 8, reducing the investment threshold and allowing for more flexible participation from investors [3].

Core Viewpoint - The NewCo model is increasingly becoming a preferred strategy for Chinese pharmaceutical companies to expand internationally, with significant financial implications and advantages over traditional business development (BD) models [1][3]. Group 1: NewCo Model Overview - NewCo refers to the establishment of a new company that holds overseas rights to a pharmaceutical product, allowing for international management and potential exit through IPO or acquisition [3]. - Compared to traditional BD models, NewCo offers advantages in collaboration structure, ownership distribution, financial flexibility, and market entry [3]. - Traditional BD models face high uncertainty after transferring pipeline rights, while NewCo allows for shared decision-making and risk management [3][4]. Group 2: Advantages of NewCo Model - The NewCo model optimizes the asset and funding matching process for innovative drugs, enabling early-stage pipelines to secure funding from U.S. venture capital without affecting domestic listings [4]. - It accelerates research and international registration processes, allowing products to enter overseas markets more quickly while reducing financial pressure on pharmaceutical companies [5]. - NewCo provides stronger control and protection for Chinese companies, allowing them to retain equity and benefit from long-term value appreciation through various revenue streams [5]. Group 3: Market Outlook and Opportunities - The NewCo model is seen as a vital pathway for Chinese pharmaceutical companies to achieve internationalization, leveraging advantages such as population demand, manufacturing capabilities, and growing innovation [8]. - The industry is expected to continue seeing growth opportunities in innovation, international expansion, and market consolidation as the NewCo trend evolves [8].

Core Insights - The innovative drug ETF (159992) has reached a scale of 10.037 billion yuan as of July 17, 2025, with an average daily trading volume of 417 million yuan since the beginning of the year, leading in both scale and liquidity among similar funds [1] - The impressive performance of innovative drugs is supported by significant policy implementations and continuous improvements in the industry fundamentals [1] Policy Highlights - The National Healthcare Security Administration and the National Health Commission have jointly issued measures to support the high-quality development of innovative drugs, proposing 16 measures to strengthen full-chain support for innovative drugs [3] R&D Support - The new policy aims to address bottlenecks in the R&D of innovative drugs by introducing a series of supportive measures, including the opening of medical insurance data and capital supply, which is expected to reduce the R&D trial-and-error costs and financing pressures for innovative drug companies [4][6] Market Access Optimization - The establishment of a dual-directory system for medical insurance and commercial insurance for innovative drugs is expected to break through the total volume limits of medical insurance, enhancing the premium space for high clinical value innovative drugs [7][8] Clinical Application Enhancement - A series of measures have been introduced to optimize market access processes, which are expected to eliminate barriers to hospital access and enhance payment flexibility, thereby shortening the clinical volume cycle for innovative drugs [9][10] Payment Expansion - By 2030, a multi-tiered medical security system is expected to be established, with basic medical insurance as the mainstay, supplemented by medical assistance and commercial health insurance [12] Market Growth Potential - The innovative drug market is anticipated to grow significantly, with A-share pharmaceutical and biotechnology companies expected to invest over 120 billion yuan in R&D in 2024. The new policies are likely to enhance the returns and accessibility of innovative drugs, leading to a substantial increase in the number of approved innovative drugs [13] - The Chinese innovative drug market is projected to grow from nearly 550 billion yuan in 2024 to over 2 trillion yuan by 2030, with a compound annual growth rate of approximately 24.1% [13] Investment Opportunities - Investors interested in the innovative drug sector can consider innovative drug ETFs (159567, 159992) and their corresponding funds to capitalize on the growth of the innovative drug industry [15]

Core Viewpoint - The Chinese innovative drug market is experiencing significant growth, driven by policy support, increased capital investment, and industry maturation, leading to a sustained release of innovative drug value [1][4][7] Group 1: Policy Support - Since 2015, a series of medical reform policies have been implemented, facilitating a profound transition from generic to innovative drugs in China [3] - In 2025, several supportive policies for innovative drugs were introduced, including optimization of clinical trial reviews and adjustments to insurance drug lists [3][4] - The establishment of a comprehensive support system for innovative drug development has been noted, aiding China's transformation into a strong player in the innovative drug sector [4] Group 2: Capital Investment - The financing environment for innovative drugs is improving, with significant increases in BD (business development) transactions and IPOs in the Hong Kong market [4][6] - In the first five months of 2025, BD transaction amounts reached $598 million, surpassing the total for 2024 [4] - The reintroduction of the fifth set of listing standards on the Sci-Tech Innovation Board is expected to stimulate investment in innovative drug companies [6] Group 3: Industry Development - The number of approved innovative drugs in China has significantly increased, with 48 new approvals in 2024, five times that of 2018 [6] - China has become a major player in the global innovative drug field, with a substantial pipeline of research and development [7] - The combination of strong national support and the maturation of innovative drug companies indicates that the industry is entering a phase of substantial returns [7]

Group 1 - The core viewpoint of the articles is that despite recent short-term fluctuations, the long-term investment value of innovative drugs, particularly ADCs, remains strong due to technological breakthroughs and market demand in China [1][3][10] - The ADC (Antibody-Drug Conjugates) market is experiencing significant growth, with the global market expected to increase from $7.9 billion in 2022 to $64.7 billion by 2030, representing a compound annual growth rate (CAGR) of 30.0% [9][10] - China's ADC market is projected to grow from 800 million yuan in 2022 to 66.2 billion yuan by 2030, with a remarkable CAGR of 72.8% [9][10] Group 2 - As of May 2025, China has approved 11 ADC drugs for various cancers, including breast cancer, lymphoma, and non-small cell lung cancer, with several more in clinical trials [3][9] - At the 2025 ASCO conference, 89 out of 184 ADC-related studies presented were from China, accounting for approximately 48.4% of the total [3][9] - In 2024, China had 20 ADC license-out transactions, maintaining the same number as the previous year, with a total transaction value of $10.24 billion, representing 20% of the total license-out transactions in China [6][9] Group 3 - The Chinese government is actively supporting the development of innovative drugs, including ADCs, as evidenced by the release of policies aimed at enhancing the pharmaceutical industry's quality [10] - The convergence of technological advancements, market demand, and supportive policies is creating a historic opportunity for Chinese ADC drugs [10] - Beyond ADCs, Chinese companies are also leading in other innovative drug research areas such as dual antibodies, second-generation immuno-oncology, and GLP-1 [10]